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Abstract
Background: Regardless the regulatory function of microRNAs (miRNA), their differential expression pattern has
been used to define miRNA signatures and to disclose disease biomarkers. To address the question of whether
patients presenting the different types of diabetes mellitus could be distinguished on the basis of their miRNA and
mRNA expression profiling, we obtained peripheral blood mononuclear cell (PBMC) RNAs from 7 type 1 (T1D), 7 type 2
(T2D), and 6 gestational diabetes (GDM) patients, which were hybridized to Agilent miRNA and mRNA microarrays.
Data quantification and quality control were obtained using the Feature Extraction software, and data distribution was
normalized using quantile function implemented in the Aroma light package. Differentially expressed miRNAs/mRNAs
were identified using Rank products, comparing T1DxGDM, T2DxGDM and T1DxT2D. Hierarchical clustering was
performed using the average linkage criterion with Pearson uncentered distance as metrics.
Results: The use of the same microarrays platform permitted the identification of sets of shared or specific
miRNAs/mRNA interaction for each type of diabetes. Nine miRNAs (hsa-miR-126, hsa-miR-1307, hsa-miR-142-3p,
hsa-miR-142-5p, hsa-miR-144, hsa-miR-199a-5p, hsa-miR-27a, hsa-miR-29b, and hsa-miR-342-3p) were shared
among T1D, T2D and GDM, and additional specific miRNAs were identified for T1D (20 miRNAs), T2D (14) and
GDM (19) patients. ROC curves allowed the identification of specific and relevant (greater AUC values) miRNAs for
each type of diabetes, including: i) hsa-miR-1274a, hsa-miR-1274b and hsa-let-7f for T1D; ii) hsa-miR-222, hsa-miR-30e
and hsa-miR-140-3p for T2D, and iii) hsa-miR-181a and hsa-miR-1268 for GDM. Many of these miRNAs targeted mRNAs
associated with diabetes pathogenesis.
Conclusions: These results indicate that PBMC can be used as reporter cells to characterize the miRNA expression
profiling disclosed by the different diabetes mellitus manifestations. Shared miRNAs may characterize diabetes as a
metabolic and inflammatory disorder, whereas specific miRNAs may represent biological markers for each type of
diabetes, deserving further attention.
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Background
MicroRNAs (miRNAs) are small noncoding single-stranded
RNAs of approximately 22 nucleotides, well-conserved
among different species. The precursors of miRNAs are
transcribed into the nucleus and several steps are required
until mature miRNAs can be exported to the cytoplasm
and incorporated into the RNA-induced silencing complex
(RISC). This process can affect gene expression at post-
translational level, leading to mRNA degradation, trans-
lational repression or both. As a consequence, the same
mRNA expression can be modulated by one or several
miRNAs, while one miRNA can regulate several genes.
Much attention has been devoted to the role of miRNAs
acting on the posttranscriptional gene control and it has
been suggested that they may be used as biomarkers of
disorders of varied etiologies [1].
MiRNAs present a tissue-specific expression pattern
[2] and are involved in the regulation of several important
cellular functions, such as cell cycle regulation, apoptosis,
differentiation and maintenance of the immune system
cell repertoire [3]. Although many factors are implicated
on gene regulation, at least one third of the transcription
control may be attributed to the action of miRNAs [4].
The probability of interaction of miRNAs with mRNAs
may be evaluated by several algorithms in several data-
bases, including TargetScan, Pictar, miRanda and others
[5-7]. The advent of microarray platforms for miRNAs
and mRNAs has provided a powerful tool to unveil new
mRNA/miRNA interactions. In this context, considering
the availability of miRNAs in tissues, plasma or in peripheral
blood, aberrant expression of miRNAs has been used as bio-
markers for neoplastic and non-neoplastic disorders [8-10].
Diabetes is one of the most prevalent chronic diseases,
affecting 6.4% of the world’s adult population [11], and
the disease may be classified into three principal types:
type 1 (T1D), type 2 (T2D), and gestational diabetes melli-
tus (GDM). T1D is an autoimmune disease characterized
by an inflammatory response, which leads to a progressive
destruction of pancreatic beta cells, resulting in deregula-
tion of glucose metabolism and insulin deficiency. T2D is
usually a non-insulin-dependent diabetes, generally associ-
ated with obesity, caused by deficient insulin secretion by
pancreatic beta-cell islets or deficient insulin action in
peripheral tissues [12]. GDM has been defined as any
degree of glucose intolerance with onset or first recognition
during pregnancy, and, in most of cases, after birth de-
livery occur the stabilization of glucose metabolism and
of the oral glucose tolerance test.
Several studies have been conducted to evaluate specif-
ically expressed miRNAs in the diverse types of diabetes,
particularly associated with the regulation of insulin pro-
duction and secretion [13-18], differentiation of human
pre-adipocytes [19], and association with T1D pathogen-
esis [20]. Other studies investigated the involvement of
differentially expressed miRNAs in T1D [3] and T2D
[21,22]; however, there is no information regarding the
comparisons of the major types of diabetes using the
same microarray platforms. In the present study, we
evaluated the mRNA and miRNA profiles of patients
presenting T1D, T2D and GDM, using the same micro-
array platforms, intending to unveil shared and privately
expressed miRNAs.
Results
The differential mRNA/miRNA expression analysis re-
vealed similarities and dissimilarities among the differ-
ent types of diabetes mellitus. Both mRNA and miRNA
analyses were performed comparing two groups; i.e.,
T1D versus GDM, T2G versus GDM and T1D versus T2D.
Statistical analysis of mRNAs by rank products compar-
ing groups of patients yielded 523 differentially expressed
transcripts when comparing T1D versus GDM, 328 tran-
scripts for T2G versus GDM, and 477 for T1D versus T2D
(P ≤ 0.001). Rank products analysis for miRNAs yielded 54
(T1D versus GDM), 28 (T2G versus GDM) and 31 (T1D
versus T2D) differentially expressed miRNAs. As seen in
Figure 1, the transcript profiles of mRNA and miRNA
of patients clearly separated them into distinct clusters.
Overall, the interaction of mRNAs with miRNAs dis-
closed several predicted interactions, which have been
previously described in databanks [23-26]; however, most
of these interactions have not been reported in association
with diabetes. The comparison between T1D and GDM
(523 mRNA and 54 miRNA differentially expressed) re-
vealed 31 predicted interactions, including 21 distinct
mRNAs and 13 distinct miRNAs. Among these 21 mRNAs,
8 were downregulated (ABCA13, HTRA3, SPTB, SLC6A8,
ANKRD22, OXTR, GYPA, and OR51E2) and 13 were
upregulated (ACTL6B, C1orf87, FEZ1, IQGAP3, DDX3Y,
EIF1AY, ZFY, COL13A1, HRH4, UTY, DLG5, MS4A2, and
SLC11A2). The analysis of miRNAs revealed that 5 out of
13 were down regulated (hsa-miR-636, hsa-miR-939, hsa-
miR-720, hsa-miR-595, and hsa-miR-623) and 8 were up
regulated (hsa-miR-338-3p, hsa-miR-342-3p, hsa-miR-30b,
has-miR-30c, hsa-miR-27a, hsa-miR-27b, hsa-miR-374a,
and hsa-miR-92a). These results are shown in Table 1.
The comparison T2D versus GDM (328 mRNAs and
28 miRNAs differentially expressed) yielded 42 predicted
interactions, encompassing 23 transcripts and 17 miRNAs
(Table 2). Among the 23 differentially expressed mRNAs,
16 were downregulated (MMP1, RASGEF1B, SLC6A8,
IL1A, EGR3, OXTR, GYPA, ORS1E2, MMP8, SEZ6L2,
HTRA3, C8orf4, NR4A1, EREG, LALBA, and CTTN)
and 7 upregulated (EIF1AY, ZFY, LPAL2, DDX3Y, SETD5,
BAGALNT3, and MLYCD). Among the 17 differentially
expressed miRNAs, 6 out of 17 were downregulated
(hsa-miR-451, hsa-miR-199a-3p, hsa-miR-595, hsa-miR-
1268, hsa-miR-181d, and hsa-miR-486-5p) and 11 were
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upregulated (hsa-miR-342-3p, hsa-miR-30b, hsa-miR-
144, hsa-miR-140-3p, hsa-miR-30e, hsa-miR-142-5p,
hsa-miR-378, hsa-miR-181a, hsa-miR-101, hsa-miR-
142-3p, and hsa-miR-324-5p) (Table 2).
Finally, the comparison T1D versus T2D (477 mRNA and
31 miRNA differentially expressed) produced 80 predicted
interactions, encompassing 42 mRNAs and 23 miRNAs.
Among the differentially expressed mRNAs, 12 were
downregulated (BATF2, SPG20, ZSWIM3, ANKRD22,
IFNG, CA1, ADAMTSL4, SETD5, TRIM36, C1orf25,
C9orf40, and PARS2) and 30 were upregulated (C1orf87,
PANX2, PDE4D, PITPNM2, RASGEF1B, FBLN2, GPR125,
SNF1LK, ABCD3, CCL20, MPHOSPH6, KRT2, STK35,
IL1A, CXCL3, SLC11A2, CRABP1, DDX3Y, SLC16A3,
IRS2, SNAI1, ZNF507, ID1, SOD2, TBKBP1, TSPYL5,
C1orf96, DFNB31, PER1, and EREG). Regarding miRNAs,
10 were downregulated (hsa-miR-342-3p, hsa-miR-720,
hsa-miR-144, hsa-miR-140-3p, hsa-miR-30e, hsa-miR-1260,
hsa-miR-1308, hsa-miR-142-5p, hsa-miR-29b, and hsa-miR-
142-3p) and 13 were upregulated (hsa-miR-27a, hsa-
miR-21, hsa-miR-130a, hsa-miR-150, hsa-miR-223,
hsa-miR-451, hsa-let-7a, hsa-let-7e, hsa-let-7f, hsa-let-7 g,
hsa-miR-20b, hsa-miR-199a-3p, and hsa-miR-103), yielding
80 interactions shown in Table 3.
As shown in Tables 1, 2 and 3, several types of mRNA/
miRNA expected interactions were observed; i. e., induction
of a miRNA and repression of an mRNA or vice versa,
and also simultaneous induction or repression of both
miRNAs and mRNAs. Several predicted interactions
were observed, many of them encompassing genes involved
in the pathogenesis of diabetes, for instance miR-30e
targeting IL1A and IRS2, miR-181a targeting IL1A,
miR-223 targeting SLC11A2, miR-29b targeting ID1,
miR-21 targeting CCL20, and many others. Figure 2 shows
mRNA/miRNA gene networks generated from data
observed in Tables 1, 2 and 3 (upper networks show all
predicted interactions, and lower networks show only
the negative correlations; i. e., increased miRNA versus
decreased mRNA or vice-versa).
To identify shared and specific miRNAs involved in
each type of diabetes, several Venn diagrams were con-
structed taking into account only the differentially expressed
miRNAs (Figure 3). After performing the multiple compari-
sons between T1D versus T2D, T1D versus GDM and T2D
versus GDM, we observed that 9 miRNAs were shared by
T1D, T2D and GDM, i.e., hsa-miR-126, hsa-miR-1307,
hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-144, hsa-miR-
199a-5p, hsa-miR-27a, hsa-miR-29b, and hsa-miR-342-3p.
Figure 1 Hierarchical clustering of mRNA (upper dendrograms) and microRNAs (lower dendrograms). Clustering analyses refer to the
comparisons of the transcript profiles (mRNA and miRNA) between T1D versus GDM (1A and 1D), between T2D versus GDM (1B and 1E), and
between T1D versus T2D (1C and 1F). As observed, the mRNA and miRNA profiles were distinct for each type of diabetes.
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These miRNAs appear in all intersections of the four
Venn diagrams shown in Figure 3. Besides the shared
miRNAs, specific miRNAs were identified for each type
of diabetes, including: i) T1D: hsa-let-7f, hsa-let-7 g,
hsa-miR-103, hsa-miR-1260, hsa-miR-1274a, hsa-miR-1274b,
hsa-miR-130a, hsa-miR-150, hsa-miR-20b, hsa-miR-21 and
hsa-miR-720, ii) T2D: hsa-miR-140-3p, hsa-miR-199a-3p,
hsa-miR-222, hsa-miR-30e and hsa-miR-451, and iii) GDM:
hsa-miR-101, hsa-miR-1180, hsa-miR-1268, hsa-miR-181a,
hsa-miR-181d, hsa-miR-26a, hsa-miR-29a, hsa-miR-29c, hsa-
miR-30b and hsa-miR-595.
The receiver operating characteristic curve (ROC curve)
is a diagram to assess sensitivity in function of the specifi-
city. It is usually used in medicine to determine the accur-
acy of a test to discriminate disease cases from normal
cases [27], and to establish a cut-off value for some diag-
nostic tests. The ROC curve can also be used to compare
more than one diagnostic performance from different la-
boratories [28]. In the present study, the ROC analysis was
used to search for potential biomarkers for each type of
diabetes. Several ROC curves were constructed for spe-
cific miRNAs, considered to be of biological relevance
Table 1 Analyses of interactions of differentially expressed miRNAs and mRNAs, considering T1D* and GDM* patients
mRNA microRNA #DIANAmT #miRanda #miRDB #miRWalk #RNAhybrid #Targetscan
ABCA13(⬇) miR-636(⬇) 1 1 1 1 1 1
HTRA3(⬇) miR-636(⬇) 1 1 0 1 1 1
ACTL6B (⬆) miR-939(⬇) 0 1 0 1 0 1
C1orf87(⬆) miR-939(⬇) 1 1 0 1 1 1
IQGAP3(⬆) miR-939(⬇) 1 1 0 1 1 1
SPTB(⬆) miR-939(⬇) 1 1 0 1 1 1
DDX3Y(⬆) miR-338-3p(⬆) 1 1 0 1 0 1
EIF1AY(⬆) miR-338-3p(⬆) 1 1 1 1 1 1
C1orf87(⬆) miR-342-3p(⬆) 0 1 0 1 0 1
SLC6A8(⬇) miR-342-3p(⬆) 1 1 1 1 1 1
ANKRD22(⬇) miR-720(⬇) 0 1 0 1 1 1
FEZ1(⬆) miR-720(⬇) 0 1 1 1 1 1
COL13A1(⬆) miR-30b(⬆) 1 1 0 1 0 1
EIF1AY(⬆) miR-30b(⬆) 1 1 0 1 1 1
ZFY(⬆) miR-30b(⬆) 1 1 0 1 1 1
COL13A1(⬆) miR-30c(⬆) 1 1 0 1 0 1
EIF1AY(⬆) miR-30b(⬆) 1 1 0 1 0 1
ZNF(⬆) miR-30b(⬆) 1 1 0 1 1 1
OXTR(⬇) miR-595(⬇) 1 1 0 1 1 1
HRH4(⬆) miR-623(⬇) 1 1 0 1 1 1
EIF1AY(⬆) miR-27a(⬆) 1 1 0 1 1 1
EIF1AY(⬆) miR-27b(⬆) 1 1 0 1 1 1
GYPA(⬇) miR-347a(⬆) 1 1 1 1 1 1
ORS51E2(⬇) miR-347a(⬆) 1 1 1 1 1 1
UTY(⬆) miR-347a(⬆) 1 1 0 1 1 1
DDX3Y(⬆) miR-92a(⬆) 1 1 0 1 0 1
DLG5(⬆) miR-92a(⬆) 1 1 0 1 0 1
FEZ1(⬆) miR-92a(⬆) 0 1 0 1 1 1
MS4A2(⬆) miR-92a(⬆) 1 1 1 1 1 1
OXTR(⬇) miR-92a(⬆) 1 1 0 1 1 1
SLC11A2(⬆) miR-92a(⬆) 1 1 0 1 0 1
*T1D – type 1 diabetes and GDM – gestational diabetes.
#Algorithms for mRNA/miRNA interactions.
Number 1 represents predicted interaction and number 0 indicates non-predicted interaction.
⬆ mRNA or miRNA upregulation and ⬇mRNA or miRNA downregulation.
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Table 2 Analyses of interactions of differentially expressed miRNAs and mRNAs, considering T2D* and GDM* patients
mRNA microRNA #DIANAmT #miRanda #miRDB #miRWalk #RNAhybrid #Targetscan
MMP1(⬇) miR-342-3p(⬆) 1 1 0 1 1 1
RASGEF1B(⬇) miR-342-3p(⬆) 1 1 0 1 1 1
SLC6A8(⬇) miR-342-3p(⬆) 1 1 1 1 1 1
EIF1AY(⬆) miR-30b(⬆) 1 1 0 1 1 1
IL1A(⬇) miR-30b(⬆) 1 1 0 0 0 0
ZFY(⬆) miR-30b(⬆) 1 0 0 0 0 0
ZFY(⬆) miR-144(⬆) 1 1 0 1 1 1
EGR3(⬇) miR-140-3p(⬆) 1 1 0 1 1 1
LPAL2(⬆) miR-140-3p(⬆) 0 0 0 1 1 1
RASGEF1B(⬇) miR-140-3p(⬆) 1 1 0 1 1 1
DDX3Y(⬆) miR-451(⬇) 1 1 0 1 0 1
OXTR(⬇) miR-451(⬇) 1 1 0 1 1 1
SETD5(⬆) miR-451(⬇) 1 1 0 1 1 1
EIF1AY(⬆) miR-30e(⬆) 1 1 1 1 1 1
IL1A(⬇) miR-30e(⬆) 1 1 1 1 1 1
ZFY(⬆) miR-30e(⬆) 1 1 1 1 1 1
EGR3(⬇) miR-142-5p(⬆) 1 1 0 1 1 1
EIF1AY(⬆) miR-142-5p(⬆) 1 1 0 1 1 1
GYPA(⬇) miR-142-5p(⬆) 1 1 0 1 1 1
OR51E2(⬇) miR-142-5p(⬆) 1 1 0 1 1 1
MMP8(⬇) miR-199a-3p(⬇) 0 1 0 1 0 0
SEZ6L2(⬇) miR-199a-3p(⬇) 0 0 0 1 0 1
B4GALNT3(⬆) miR-199a-3p(⬇) 1 1 0 1 1 0
EIF1AY(⬆) miR-199a-3p(⬇) 1 1 0 1 1 0
OXTR(⬇) miR-378(⬆) 1 1 0 1 1 1
MLYCD(⬆) miR-595(⬇) 1 1 0 1 1 0
OXTR(⬇) miR-595(⬇) 1 1 0 1 1 1
IL1A(⬇) miR-181a(⬆) 1 1 1 1 1 1
OR51E2(⬇) miR-181a(⬆) 1 1 0 1 1 1
SLC6A8(⬇) miR-1268(⬇) 0 1 0 1 1 1
B4GALNT3(⬆) miR-1268(⬇) 0 1 0 1 1 1
GYPA(⬇) miR-181d(⬇) 1 1 1 1 1 1
IL1A(⬇) miR-181d(⬇) 1 1 1 1 1 1
HTRA3(⬇) miR-101(⬆) 1 1 1 1 1 1
C8orf4(⬇) miR-101(⬆) 1 1 1 1 1 1
NR4A1(⬇) miR-486-5p(⬇) 1 0 0 1 1 1
EREG(⬇) miR-142-3p(⬆) 1 1 0 1 1 1
LALBA(⬇) miR-142-3p(⬆) 1 1 0 1 1 1
OR51E2(⬇) miR-142-3p(⬆) 1 1 0 1 1 1
CTTN(⬇) miR-142-3p(⬆) 1 1 0 1 1 1
LALBA(⬇) miR-324-5p(⬆) 1 1 0 1 1 1
ZFY(⬆) miR-144(⬆) 1 1 0 1 1 1
*T2D – type 2 diabetes and GDM – gestational diabetes.
#Algorithms for mRNA/miRNA interactions.
Number 1 represents predicted interaction and number 0 indicates non-predicted interaction.
⬆ mRNA or miRNA upregulation and ⬇mRNA or miRNA downregulation.
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Table 3 Analyses of interactions of differentially expressed miRNAs and mRNAs, considering T1D* and T2D* patients
mRNA microRNA #DIANAmT #miRanda #miRDB #miRWalk #RNAhybrid #Targetscan
BATF2(⬇) miR-342-3p(⬇) 1 1 0 1 1 1
C1orf87(⬆) miR-342-3p(⬇) 0 1 0 1 0 1
PANX2(⬆) miR-342-3p(⬇) 1 1 0 1 1 1
PDE4D(⬆) miR-342-3p(⬇) 0 0 0 1 0 1
PITPNM2(⬆) miR-342-3p(⬇) 1 1 0 1 1 1
RASGEF1B(⬆) miR-342-3p(⬇) 1 1 0 1 1 1
SPG20(⬇) miR-342-3p(⬇) 1 1 0 1 1 1
ZSWIM3(⬇) miR-342-3p(⬇) 1 1 0 1 1 1
ANKRD22(⬇) miR-720(⬇) 0 1 0 1 1 1
FBLN2(⬆) miR-27a(⬆) 1 1 0 1 1 1
GPR125(⬆) miR-27a(⬆) 1 1 0 1 1 1
IFNG(⬇) miR-27a(⬆) 1 1 0 1 1 1
PITPNM2(⬆) miR-27a(⬆) 1 1 0 1 1 1
SNF1LK(⬆) miR-27a(⬆) 1 1 1 1 1 1
ABCD3(⬆) miR-21(⬆) 1 1 1 1 1 1
CA1(⬇) miR-21(⬆) 0/1 0/1 0 1 0 1
CCL20(⬆) miR-21(⬆) 1 1 1 1 1 1
ABCD3(⬆) miR-130a(⬆) 1 1 0 1 1 0
ABCD3(⬆) miR-144(⬇) 0 1 0 0 0 0
MPHOSPH6(⬆) miR-144(⬇) 1 1 1 1 1 1
KRT2(⬆) miR-140-3p(⬇) 1 1 0 1 1 1
RASGEF1B(⬆) miR-140-3p(⬇) 1 1 0 1 1 1
STK35(⬆) miR-140-3p(⬇) 1 1 0 1 1 1
IL1A(⬆) miR-150(⬆) 1 1 1 1 1 1
ADAMTSL4(⬇) miR-223(⬆) 1 0 0 1 1 1
CXCL3(⬆) miR-223(⬆) 0 0 0 1 0 0
SLC11A2(⬆) miR-223(⬆) 1 1 1 1 1 1
ADAMTSL4(⬇) miR-451(⬆) 1 1 0 1 1 0
CRABP1(⬆) miR-451(⬆) 1 1 0 1 1 0
DDX3Y(⬆) miR-451(⬆) 1 1 0 1 0 1
SETD5(⬇) miR-451(⬆) 1 1 0 1 1 1
SLC16A3(⬆) miR-451(⬆) 1 1 0 1 1 1
ANKRD22(⬇) miR-30e(⬇) 1 1 1 1 1 1
GPR125(⬆) miR-30e(⬇) 1 1 1 1 1 1
IL1A(⬆) miR-30e(⬇) 1 1 1 1 1 1
IRS2(⬆) miR-30e(⬇) 1 1 0 1 1 1
PITPNM2(⬆) miR-30e(⬇) 1 1 1 1 1 1
SETD5(⬇) miR-30e(⬇) 0 1 1 1 1 1
SNAI1(⬆) miR-30e(⬇) 1 1 1 1 1 1
ZNF507(⬆) miR-30e(⬇) 1 1 0 1 1 1
ID1(⬆) miR-1260(⬇) 0 1 0 1 1 1
STK35(⬆) miR-1308(⬇) 0 1 0 1 1 1
SOD2(⬆) miR-142-5p(⬇) 1 1 0 1 1 0
TRIM36(⬇) miR-142-5p(⬇) 1 0 0 0 0 1
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those exhibiting values of area under curve (AUC) greater
than 0.8, i.e., high sensibility and high specificity. Accord-
ingly, the hsa-miR-1274a, hsa-miR-1274b and hsa-let-7f pre-
sented better results for T1D; hsa-miR-222, hsa-miR-30e
and hsa-miR-140-3p for T2D; and hsa-miR-181a and
hsa-miR-1268 for GDM patients (Figure 4).
Discussion
The analysis of miRNA expression profile displayed by
the three types of diabetes showed distinct hybridization
signatures according to the type of diabetes, in accord-
ance with the results reported by us in a previous study
evaluating the mRNA profiling of these patients [29].
Table 3 Analyses of interactions of differentially expressed miRNAs and mRNAs, considering T1D* and T2D* patients
(Continued)
C1orf25(⬇) let-7a(⬆) 1 1 0 1 1 1
C9orf40(⬇) let-7a(⬆) 0 1 0 1 1 1
MPHOSPH6(⬆) let-7a(⬆) 1 1 0 1 1 1
PARS2(⬇) let-7a(⬆) 1 1 1 1 1 1
TBKBP1(⬆) let-7a(⬆) 1 1 0 1 1 1
TSPYL5(⬆) let-7a(⬆) 0 1 0 1 1 1
C9orf40(⬇) let-7e(⬆) 0 1 0 1 1 1
IRS2(⬆) let-7e(⬆) 1 1 0 1 1 1
MPHOSPH6(⬆) let-7e(⬆) 1 1 0 1 1 1
PARS2(⬇) let-7e(⬆) 1 1 1 1 1 1
TBKBP1(⬆) let-7e(⬆) 1 1 0 1 1 1
TSPYL5(⬆) let-7e(⬆) 0 1 0 1 1 1
C1orf25(⬇) let-7f(⬆) 0 1 0 1 0 1
C9orf40(⬇) let-7f(⬆) 0 1 0 1 1 1
MPHOSPH6(⬆) let-7f(⬆) 1 1 0 1 1 1
PARS2(⬇) let-7f(⬆) 1 1 0 1 0 1
TBKBP1(⬆) let-7f(⬆) 1 1 0 1 0 1
TSPYL5(⬆) let-7f(⬆) 0 1 0 1 1 1
C1orf25(⬇) let-7 g(⬆) 1 1 0 1 1 1
MPHOSPH6(⬆) let-7 g(⬆) 1 1 0 1 1 1
PARS2(⬇) let-7 g(⬆) 1 1 1 1 1 1
TBKBP1(⬆) let-7 g(⬆) 1 1 0 1 1 1
TSPYL5(⬆) let-7 g(⬆) 0 1 0 1 1 1
C1orf96(⬆) miR-29b(⬇) 1 1 1 1 1 1
DFNB31(⬆) miR-29b(⬇) 1 1 0 1 1 1
ID1(⬆) miR-29b(⬇) 1 1 0 1 1 1
IFNG(⬇) miR-29b(⬇) 1 1 0 1 1 1
PER1(⬆) miR-29b(⬇) 1 1 0 1 1 1
PITPNM2(⬆) miR-29b(⬇) 1 1 0 1 1 1
KRT2(⬆) miR-20b(⬆) 1 1 0 1 1 1
TRIM36(⬇) miR-20b(⬆) 1 1 0 1 1 1
MPHOSPH6(⬆) miR-199a-3p(⬆) 1 1 1 1 1 1
TRIM36(⬇) miR-199a-3p(⬆) 1 1 1 1 1 1
EREG(⬆) miR-142-3p(⬇) 1 1 0 1 1 1
RASGEF1B(⬆) miR-103(⬆) 1 1 0 1 1 1
TBKBP1(⬆) miR-103(⬆) 1 1 0 1 0 1
*T1D – type 1 diabetes and T2D – type 2 diabetes.
#Algorithms for mRNA/miRNA interactions.
Number 1 represents predicted interaction and number 0 indicates non-predicted interaction.
⬆ mRNA or miRNA upregulation and ⬇mRNA or miRNA downregulation.
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The major focuses on the analysis of mRNA/miRNA sig-
natures encompassing T1D, T2D and GDM patients in-
cluded: i) pinpoint miRNAs shared among the three
types of diabetes; ii) select miRNAs specific for each type
of diabetes; iii) disclose putative mRNAs targeted by the
differentially expressed miRNAs; and iv) identify non-
described miRNAs associated with each type of diabetes.
All selected miRNAs were detected in at least 3 out of 6
algorithm analyses used in the present study.
MiRNAs play regulatory roles in many biological pro-
cesses associated with diabetes, including adipocyte differ-
entiation, metabolic integration, insulin resistance and
appetite regulation [30]. The role of miRNAs in diabetes
has been associated with several pathogenic features, in-
cluding: i) miR-410, miR-200a and miR-130a regulate se-
cretion of insulin in response to stimulatory levels of
glucose, and overexpression of miR-410 enhances the
levels of glucose-stimulated insulin secretion [18]; ii)
miRNA-143 is upregulated during differentiation of
human pre-adipocytes [19]; iii) miR-30d is upregulated
in pancreatic beta-cells and collaborates for increasing
insulin gene expression [17]; iv) miR-9 acts in the fine-
tuning of glucose metabolism [14]; v) miR-375 is
involved on the control of insulin gene expression and
secretion [13,15]; vi) overexpression of miR-29 represses
insulin-stimulated glucose uptake and may result in insulin
resistance [31].
Considering that 9 miRNAs were shared among the
three types of diabetes, including hsa-miR-126, hsa-miR-144,
hsa-miR-27a, hsa-miR-29b, hsa-miR-1307, hsa-miR-142-3p,
hsa-miR-142-5p, hsa-miR-199a-5p, and hsa-miR-342-
3p, we may suppose that these miRNAs are associated
with diabetes per se.
MiR-126 has been associated with immune response
of adipose tissue and macrophage infiltration into the
adipose tissue [32]. It is expressed in endothelial cells
and contributes to the endothelial homeostasis and vas-
cular integrity [33]. In diabetic patients, alteration in
Figure 2 Networks between miRNAs and mRNAs. The relationship between miRNAs and mRNAs were evaluated by constructing networks using
the Cytoscape software. (A) Upper networks show all interactions described in Tables 1, 2 and 3, and (B) lower networks show only the negative
correlations, i.e., increased miRNA versus decreased mRNA or vice-versa. Red circles represent miRNAs and the grey ones represent mRNA.
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miR-126 expression may inhibit endothelial progenitor
cell proliferation, migration, and may induce apoptosis
[34]. High glucose concentration is associated with re-
duced miR-126 content in endothelial apoptotic bodies
[21], and a positive association between miR-126 expres-
sion and myocardial infarction has been observed in dia-
betic patients, probably due to the role of miR-126 on
platelet function [35].
MiR-144, miR-27a and miR-29b present a more rele-
vant role on diabetes. MiR-144 targets IRS1 (insulin re-
ceptor substrate-1), a gene highly involved in insulin
signaling pathway, and upregulation of this miRNA exhibits
a linear relationship with the glycemic status in T2D pa-
tients [22]. Thus, the control of miR-144 expression may be
a potential therapeutic target for T2D patients, deserving
further studies.
MiR-27a together with miR-150, miR-192, miR-320a,
and miR-375 regulate several biological events related to
the pathogenesis of diabetes [22,36-38]. MiR-27a has been
associated with hyperglycemia and metabolic syndrome in
T2D patients: i) upregulation of this miRNA has been ob-
served in hyperglycemic rats exhibiting T2D [39]; ii) its
expression is associated with the fasting glucose level, sug-
gesting its potential role in the early-phase hyperglycemia
[40]; iii) considering that miR-27a has a potential
angiogenic function, its downregulation in diabetes
patients should reduce the angiogenic potential of
endothelial progenitor cells in diabetes [34]. In the present
study, miR-27a was highly expressed in T1D followed by
T2D and GDM. Although there are no studies evaluating
the role of miR-27a in T1D, this miRNA may be involved
in shared mechanisms for hyperglycemia control in the
major types of diabetes.
Several studies report that the miR-29 family, particu-
larly, miR-29b has a role in diabetes: i) in the T2D rat
model (Goto-Kakizaki), overexpression of miR-29 family
represses insulin-stimulate glucose uptake, facilitating in-
sulin resistance [31]; ii) miR-29 family members (miR-29a,
miR-29b, and miR-29c) are expressed in mouse pancreatic
beta-cells, and their expression increases with the age of
Figure 3 Venn diagrams showing common and specific microRNAs for the three types of diabetes. The central intersection of the upper
diagram shows the nine shared miRNAs among T1D, T2D and GDM, the upper right intersection shows the 5 miRNAs specific for T2D, the upper
left intersection shows the 11 miRNAs specific for T1D, and the middle lower intersection shows the 10 miRNAs specific for GDM patients. Lower
Venn diagrams identify specific miRNAs for each type of diabetes (bold letters), as well as the shared ones.
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prediabetic NOD mice [41], contributing to insulin resist-
ance in animal model of diabetes T2D [31]; iii) miR-29
overexpression downregulates glucose-induced insulin
secretion in human islet cells [41]; iv) miR-29b is highly
expressed in neurons of the retinal ganglion cells of dia-
betic rats, suggesting a role of miR-29b in the pathogen-
esis of diabetic retinopathy [42]; v) besides neurons,
miR-29b has been associated with progression of renal
fibrosis, irrespective of the etiology, including diabetic
nephropathy [43]. In concert, these findings indicate
that the miR-29b and other members of this family may
contribute to diabetes pathogenesis and diabetes micro-
vascular complications.
No association with diabetes has been described for miR-
1307, miR-142-3p, miR-142-5p, miR-199a-5p and miR-342-
3p; however, miR-142-5p and miR-142-3p have been
reported as negative regulators of CD4 T cells, and in-
creased expression of miR-142-5p and miR-142-3p is
reported in systemic lupus erythematosus, contributing
to reverse T cell hyperactivity, inhibiting antibody produc-
tion, reducing autoimmune activity and IgG production
[44]. Deregulation of some of these miRNAs has been
associated with carcinogenesis: i) miR-142-3p with acute
myeloid leukemia [45], T-cell leukemogenesis [46], esopha-
geal squamous cell carcionoma [47], and hepatocellular
carcinoma [48]; ii) miR-142-5p with T cell chronic
lymphocytic leukemia [49] and in pediatric brain tumors
[50], and iii) miR-199a-5p with hepatocellular carcinoma
[51,52], ovarian cancer [53], and oral squamous cell car-
cinoma [54]. In addition, miR-342-3p has been associated
with cellular proliferation [55], and has been suggested
as a potential biomarker for multiple myeloma [56] and
prion disease [57]. Interestingly, miR-342-3p was associ-
ated with obesity in mice [58], and the possible link be-
tween this miRNA and obesity is glucagon, a potential
target for miR-342-3p. Furthermore, miR-342-3p is as-
sociated with immune response, and it is upregulated in
activated B cells [59]. Therefore, it is possible that the
role of miR-342-3p in obesity and its association with
immune response may link this miRNA with diabetes.
To discuss specific miRNAs for each type of diabetes,
we selected only those presenting high values of area
under curve (AUC = 1.0) of the ROC curves (Figure 4).
Considering that: i) the number of differentially expressed
Figure 4 Identification of most relevant specific miRNAs for each diabetes type. The values of the area under the curve (AUC) were
estimated for all specific miRNAs obtained after the multiple comparisons among the three types of diabetes as shown in Figure 3. MiRNAs
exhibiting high AUC values are highlighted within blue rectangles.
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miRNAs is very high, ii) microRNA/mRNA interactions
are similarly high, and iii) the number of patients evalu-
ated in each group of diabetes of the present study is low,
miRNAs exhibiting high AUC may represent those with
greater potential to act as biomarker for larger studies. For
T1D, let-7f, miR-1274a and miR-1274b fit this as-
sumption. Overall, let-7 family members act as tumor
suppressors [60,61], but the Lin28/let-7 pathway regu-
lates glucose metabolism in different organs, and the
treatment with anti-let7 has been suggested as a potential
therapy for T2D [62]. The miR-1274a and miR-1274b
have never been studied in diabetes, and some authors
believe that they represent a fragment of tRNA, without
known function [63].
For T2D patients, hsa-miR-140-3p, hsa-miR-222 and
hsa-miR-30e were induced and exhibited AUC =1.0. The
miR-222 overexpression has also been associated with
the development of GDM [64], and is overexpressed in
T2D animal models [39] exhibiting obesity [65], and in
pancreatic cancer [66]. Mir-140-3p targets the SIRT1
(sirtuin 1) gene, and reduction of miR-140-3p levels has
been associated with calorie restriction [67]. SIRT1 is
increased in response to a long-term calorie restriction
in a tissue-specific manner [68,69]. Although no associ-
ation has been reported with diabetes, miR-30e is involved
with adipose tissue dysfunction and obesity, as observed
for T2D [70]. In addition, miR-30 family members are
responsible for expression of mesenchymal proteins
during pancreatic fibrosis [71], and miR-30d is upregu-
lated by glucose and increased insulin gene expression,
suggesting that miR-30d may be a negative regulator for
insulin gene expression [17].
Regarding GDM, two miRNA exhibited AUC =1.0: i)
hsa-miR-1268 that was induced and ii) hsa-miR-181a
that was repressed in relation to T1D and T2D. The few
studies evaluating miR-1268 are inconclusive about its
function. On the other hand, miR-181a has been consid-
ered to be a link between adipose tissue dysfunction and
the development of obesity-associated disorders includ-
ing T2D [72]. Considering that the overexpression of
miR-181a induces hepatic insulin resistance in T2D pa-
tients, this miRNA has been suggested as potential diag-
nostic marker for this type of diabetes [72]; however,
miR-181a is also overexpressed in children with new on-
set T1D [73]. Since the induction of miR-181a has been
previously associated with T1D and T2D, and since this
miRNA was repressed in GDM when compared to T1D
and T2D, miR-181a deserves further studies in GDM in
terms of pathophysiology and disease marker.
Conclusions
The present study revealed shared miRNAs among the
major types of diabetes, which were also observed in
the MiRDisease database [74], including hsa-miR-29b,
miR-142-3p and hsa-miR-142-5p. Many of these shared
miRNAs have been associated with metabolic pathways,
immunological processes and tumorigenesis. Some of these
miRNAs were also shared by other immune-mediated
or chronic inflammatory diseases, including psoriasis
(hsa-miR-142-3p) and lupus nephritis (hsa-miR-150 and
hsa-miR-142-5p).
This is the first miRNA study involving the three major
groups of diabetes using the same microarray platform,
showing that: i) the miRNA signature of each diabetes
subset is distinct, ii) shared miRNAs in the major types of
diabetes are associated with biological functions associated
with disease pathogenesis, iii) privately expressed miRNAs
may be used for further and larger studies as disease
biomarkers.
Methods
Patients
Peripheral blood mononuclear cells (PBMCs) were
obtained from 20 adult patients, i.e., 7 presenting T1D
(aged 18–27 years), 7 with T2D (aged 41–61 years) and 6
with GDM (aged 29 to 39 years), followed-up at the
Outpatient Clinics of the Division of Endocrinology,
Faculty of Medicine of Ribeirao Preto, University of
Sao Paulo, Brazil. The demographic, laboratory and
treatment features of T1D, T2D, and GDM patients are
shown in Table 4. The local Ethics Committee approved
the protocol of the study (# 9153/2008) and informed
written consents were obtained for all patients. Exclusion
criteria included recent episodes of ketoacidosis, active ne-
phropathy, proliferative retinopathy, diabetic foot, high
HDL (high-density lipoprotein) levels and diagnosed car-
diovascular diseases.
Blood collection and RNA samples
Twenty mL of peripheral blood cells were collected and
used for isolation of PBMCs by gradient density (Ficoll-
Hypaque- Sigma, St. Louis, MO). Total RNA was ob-
tained using the Trizol reagent (Invitrogen, Carlsbad,
CA), according to the manufacturer’s instructions. RNA
concentrations and ratios were checked with the Nano-
Drop ND-1000 spectrophotometer (NanoDrop Products,
Wilmington, DE) and RNA quality was assessed using
the 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA). All RNA samples exhibited high integrity numbers
(RIN) ≥ 9.0.
Oligo microarrays
Total mRNA was hybridized to one-color Agilent whole
human genome 4x44K oligo microarray platforms (Agi-
lent Technologies, Santa Clara, CA), containing ~41.000
transcripts, according to manufacturer’s instructions.
MiRNA microarray was performed using Agilent human
miRNA platform (v3) 8x15K (Agilent Technologies). After
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hybridization procedures, the slides were scanned using a
Microarray Scanner with Surescan High-Resolution Tech-
nology (Agilent Technologies). A complete file providing
the hybridization profiles of all samples as well as the quan-
titative data and experimental conditions are available in
the ArrayExpress database [75] through the following
account numbers: T1D (E-MEXP-3348), T2D (E-MEXP-
3287) and GDM (E-MEXP-3349) for mRNAs, and T1D
(E-MEXP-3409), T2D (E-MEXP-3373) and GDM
(E-MEXP-3382) for miRNAs. Although these files were
recorded into the ArrayExpress database at different dates,
the hybridizations were performed at the same period but
not in the same date, using the same batch of mRNA and
miRNA microarray platforms.
Data quantification and normalization
Data quantification and quality control were performed
using the Feature Extraction (FE) software version 11.0
(Agilent Technologies). Expression data were loaded into
R environment [76]. Background adjustment was done
by subtracting median background values from the
median expression values obtained by FE, and data
were subsequently log-transformed. Finally, all the data
distribution was normalized by quantile function using
the Aroma light package [77,78].
Rank products statistical analysis
Differentially expressed mRNAs and miRNAs were identi-
fied using the Rank products non-parametric method by
the R package RankProd [79]. Genes were considered to be
of interest if P-values and percentage of false positive pre-
dictions (pfp) were smaller than 0.001. This test was used
to perform paired analysis between T1D versus GDM, T2D
versus GDM and T1D versus T2D for mRNA and miRNA
microarrays. Hierarchical clustering of differentially
expressed genes was performed using average linkage cri-
terion and Pearson uncentered distance as a metric.
MicroRNA target prediction
We searched for miRNA targets using publicly available
predictions. Variables selected for best targets included
those present in at least three algorithms, using miRWalk,
Table 4 Demographical, laboratory, and treatment features of type 1 (T1D), type 2 (T2D) and gestational (GDM)
diabetic patients
Subjects Age
(years)
Gender Insulin
regular/NPH
Duration of
diabetes (years)
Blood glucose
(mg/dL)
Glycated hemoglobin
(%)
Metformin
(mg/day)
Duration of
pregnancy (weeks)
T1DM-02 23 M Yes 13 197 8.3 - -
T1DM-03 24 M Yes 6 260 10 - -
T1DM-04 18 M Yes 8 23 7.2 - -
T1DM-05 23 M Yes 20 178 10.1 - -
T1DM-06 21 F Yes 8 223 7.8 - -
T1DM-12 27 F Yes 10 257 10.4 - -
T1DM-15 22 F Yes 13 143 8.3 - -
Mean ± SD 22.57 ± 2.76 11.14 ± 4.70 183 ± 82.08 8.87 ± 1.27
T2DM-04 49 M No 8 130 7.5 2550 -
T2DM-05 42 M Yes 11 53 5.1 1700 -
T2DM-09 52 M No 10 100 6.6 1700 -
T2DM-11 41 F Yes 3 92 10.2 2550 -
T2DM-12 43 F No 4 173 10.7 2550 -
T2DM-13 60 F Yes 20 306 10.9 0 -
T2DM-16 56 F Yes 20 295 12 2550 -
T2DM-17 61 F Yes 20 101 7.8 2550 -
Mean ± SD 50.5 ± 8.05 12 ± 7.15 156.25 ± 95.35 8.85 ± 2.43
GDM-09 33 F No 80 5 - 35
GDM-10 29 F Yes 89 5.8 - 37
GDM-12 39 F No 72 5.7 - 32
GDM-13 29 F Yes 92 5.2 - 28
GDM-14 30 F No 82 5 - 34
GDM-16 38 F Yes 59 9.1 - 34
Mean ± SD 33 ± 4.51 79 ± 12.06 5.96 ± 1.57 33.33 ± 3.07
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miRanda, RNAhybrid, and TargetScan [23-26]. The algo-
rithm GenMir++ (Generative model for miRNA regulation)
[80] was used to evaluate interactions of the differentially
expressed mRNAs and miRNAs, according to their expres-
sion profiles, to identify the best candidate interactions
using Bayesian inferences. The mRNA/miRNA networks
were performed using Cytoscape software [81]. Intending to
find association of differentially expressed miRNAs with
complex disease, miR2Disease databases [74] were also used.
ROC curve
Differentially expressed miRNAs were further ranked ac-
cording to sensitivity and specificity to find the best candi-
dates between T1D vs. T2D, T1D vs. GDM and T2D vs.
GDM groups. The criteria for biomarker selection were
sensitivity and specificity ≥ 80%, as determined using gen-
eral logistic models (glm) in the R environment followed
by ROC curve analyses using ROCR package [82].
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